Summary
58.07 0.19(0.33%)11/21/2024
Bristol-Myers Squibb Co. (BMY)
BMY reported last earnings on 2024-10-31 after the market. An EPS of $1.8 was observed compared to an estimated EPS of $1.49, resulting in a surprise value of $0.31. A revenue of $11,892 million was observed compared to an estimated revenue of $11,264 million, resulting in a surprise value of $628 Million.
Bristol-Myers Squibb Co. (BMY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.33 | -0.42 | 11.62 | 18.75 | 34.16 | 18.94 | 17.10 | 18,046.01 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Earnings
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Strong Buy |
| ROE | Strong Buy |
| ROA | Buy |
| Debt/Equity | Strong Sell |
| P/E | Sell |
| P/B | Strong Sell |
| Trading Data | ||
| Close | 58.07 | |
| Open | 58.16 | |
| High | 58.19 | |
| Low | 57.48 | |
| Volume | 936,437 | |
| Change | 0.19 | |
| Change % | 0.33 | |
| Avg Volume (20 Days) | 10,055,390 | |
| Volume/Avg Volume (20 Days) Ratio | 0.09 | |
| 52 Week Range | 39.35 - 61.08 | |
| Price vs 52 Week High | -4.93% | |
| Price vs 52 Week Low | 47.57% | |
| Range | -0.75 | |
| Gap Up/Down | -0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 107,290 | |
| EBIDTA | 18,172,000,256 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 2.2361 | |
| WallStreet Target Price | 52.25 | |
| Book Value | 8.1350 | |
| Earnings Per Share | -3.1000 | |
| EPS Estimate Current Quarter | -4.4400 | |
| EPS Estimate Next Quarter | 1.7500 | |
| EPS Estimate Current Year | 0.5600 | |
| EPS Estimate Next Year | 6.9200 | |
| Diluted EPS (TTM) | -3.1000 | |
| Revenues | ||
| Profit Marging | -0.1350 | |
| Operating Marging (TTM) | 0.1925 | |
| Return on asset (TTM) | 0.0539 | |
| Return on equity (TTM) | -0.2533 | |
| Revenue TTM | 45,533,999,104 | |
| Revenue per share TTM | 22.2120 | |
| Quarterly Revenue Growth (YOY) | 0.0470 | |
| Quarterly Earnings Growth (YOY) | -0.0890 | |
| Gross Profit (TTM) | 36,378,000,000 | |
| Dividends | ||
| Dividend Share | 2.3400 | |
| Dividend Yield | 0.0534 | |
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 6.9300 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.3249 | |
| Revenue Enterprise Value | 2.8226 | |
| EBITDA Enterprise Value | 6.5597 | |
| Shares | ||
| Shares Outstanding | 2,027,100,032 | |
| Shares Float | 2,022,964,812 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.11 | |
| Institutions (%) | 80.49 | |
11/21 08:00 EST - fool.com
Is Bristol Myers Squibb Stock a Buy?
Is Bristol Myers Squibb Stock a Buy?
Is Bristol Myers Squibb Stock a Buy?
Is Bristol Myers Squibb Stock a Buy?
11/21 04:33 EST - fool.com
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
11/20 10:06 EST - zacks.com
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
11/19 16:05 EST - seekingalpha.com
Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Jefferies London Healthcare Conference November 19, 2024 4:30 AM ET Company Participants David Elkins - CFO Unidentified Company Representative On to the next fireside chat. And again, thanks, everyone, for your attendance.
Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Jefferies London Healthcare Conference November 19, 2024 4:30 AM ET Company Participants David Elkins - CFO Unidentified Company Representative On to the next fireside chat. And again, thanks, everyone, for your attendance.
11/19 06:59 EST - businesswire.com
Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--BMS' Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms.
Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--BMS' Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms.
11/18 13:24 EST - benzinga.com
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.
11/17 11:47 EST - seekingalpha.com
Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its oncology and neuroscience franchises. So, Yervoy's sales amounted to $642 million in the third quarter of 2024, increasing by 10.9% year-on-year and 1.9% quarter-on-quarter....
Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its oncology and neuroscience franchises. So, Yervoy's sales amounted to $642 million in the third quarter of 2024, increasing by 10.9% year-on-year and 1.9% quarter-on-quarter....
11/17 08:44 EST - 247wallst.com
6 of Wall Street's Most Beloved High-Yield Stocks Are On Sale
Key Points Yields have drifted higher since the Federal Reserve cut rates in September.
6 of Wall Street's Most Beloved High-Yield Stocks Are On Sale
Key Points Yields have drifted higher since the Federal Reserve cut rates in September.
11/15 08:23 EST - businesswire.com
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite.
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® plus Yervoy® for the First-Line Treatment of Adult Patients with Microsatellite.
11/15 06:59 EST - businesswire.com
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARE--Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of advanced ROS1-Positive Non-Small Cell Lung Cancer.
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARE--Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of advanced ROS1-Positive Non-Small Cell Lung Cancer.
11/14 18:49 EST - reuters.com
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.
11/14 08:00 EST - fool.com
2 Beaten-Down Dividend Stocks to Buy and Hold
They're down, but they aren't out, at least not in the eyes of patient investors.
2 Beaten-Down Dividend Stocks to Buy and Hold
They're down, but they aren't out, at least not in the eyes of patient investors.
11/12 19:41 EST - zacks.com
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.
11/12 12:48 EST - benzinga.com
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).
11/12 11:36 EST - proactiveinvestors.com
AbbVie's loss is Bristol Myers Squibb's gain - analyst
Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed. AbbVie stock took a $38 billion hit on Monday after the company revealed that Phase 2 trials of its...
AbbVie's loss is Bristol Myers Squibb's gain - analyst
Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed. AbbVie stock took a $38 billion hit on Monday after the company revealed that Phase 2 trials of its...
11/12 08:53 EST - marketwatch.com
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.
11/12 07:22 EST - forbes.com
Buy, Sell, Or Hold BMY Stock?
Bristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November 11, after its peer AbbVie (NYSE; ABBV) announced that two of its mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics,...
Buy, Sell, Or Hold BMY Stock?
Bristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November 11, after its peer AbbVie (NYSE; ABBV) announced that two of its mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics,...
11/11 16:08 EST - seekingalpha.com
Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, Global Drug Development Robert Plenge - EVP, Chief Research Officer Conference Call Participants...
Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, Global Drug Development Robert Plenge - EVP, Chief Research Officer Conference Call Participants...
11/11 14:50 EST - zacks.com
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
BMY has been having a good run for the past three months. The stock recently touched a 52-week high.
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
BMY has been having a good run for the past three months. The stock recently touched a 52-week high.
11/11 11:00 EST - marketwatch.com
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.